Global Eosinophilic Esophagitis Market Size to Surpass US$ 1,037.2 Million by 2028, Says Coherent Market Insights (CMI) SEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global eosinophilic esophagitis market is estimated to be valued at US$ 138.4 million in 2021 and is expected to...

EsoCap secures new funding EsoCap successfully closes a private financing round, with investments from existing and new investorsThe new funding was facilitated by EsoCap benefitting from a unique programme implemented by the...

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101ESO-101, EsoCap’s lead product candidate, consists of a capsule with a...

EsoCap – unique targeted application platform to treat the upper gastrointestinal tract EsoCap’s targeted application technology drastically increases mucosal contact time and enables effective local treatment of various esophageal diseases for the first timeProof of principle in human...

PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and...